Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 0 · 0%High 1 · 50%

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy (very low certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.88 [0.56, 1.38]
3 studies · 739 participants
Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… leads to lower progression‐free survival (PFS) compared with placebo after chemotherapy (maintenance therapy) (high certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.34 [0.28, 0.42]
4 studies · 1677 participants
High